0001493152-23-040113.txt : 20231109 0001493152-23-040113.hdr.sgml : 20231109 20231109171512 ACCESSION NUMBER: 0001493152-23-040113 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biofrontera Inc. CENTRAL INDEX KEY: 0001858685 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473765675 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40943 FILM NUMBER: 231393747 BUSINESS ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 781-245-1325 MAIL ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 form8-k.htm
false 0001858685 0001858685 2023-11-09 2023-11-09 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2023-11-09 2023-11-09 0001858685 BFRI:PreferredStockPurchaseRightsMember 2023-11-09 2023-11-09 0001858685 BFRI:WarrantsToPurchaseCommonStockMember 2023-11-09 2023-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 9, 2023

 

Biofrontera Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40943   47-3765675

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

120 Presidential Way, Suite 330

Woburn, Massachusetts

   01801
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 245-1325

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.001 per share   BFRI   The Nasdaq Stock Market LLC
         
Preferred Stock Purchase Rights       The Nasdaq Stock Market LLC
         
Warrants to purchase common stock   BFRIW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 9, 2023, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the three and nine months ended September 30, 2023. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K.

 

The Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with United States generally accepted accounting principles, or GAAP. Pursuant to the requirements of Regulation G, the Company has provided within the press release quantitative reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

 

The information contained in this Item 2.02 in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

99.1   Press release dated November 9, 2023
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

  

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

November 9, 2023 Biofrontera Inc.
(Date) (Registrant)
   
  /s/ E. Fred Leffler III
  E. Fred Leffler, III
  Chief Financial Officer

 

  

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Biofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update

 

Conference call begins at 10:00 a.m. Eastern time on Friday, November 10, 2023

 

WOBURN, Mass. (November 9, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and nine months ended September 30, 2023 and provided a business update.

 

Highlights from the third quarter of 2023 and subsequent weeks included the following:

 

●Total revenues were $8.9 million, an increase of 106% from the comparable prior-year period
●Cash and cash equivalents were $3.4 million and equity investment in shares of Biofrontera AG was valued $3.3 million, both as of September 30, 2023
●Subsequent to the close of the quarter, raised $4.5 million in a registered direct offering priced at-the-market
●Appointed life sciences industry veteran Heikki Lanckriet, Ph.D. to the Board of Directors
●Hired Samantha Widdicombe as Senior Director to support and strengthen commercial relationships with key strategic customer accounts
●Announced positive results from a Phase 1 safety study evaluating photodynamic therapy (PDT) with three tubes of Ameluz®
●Announced last patient enrolled in a Phase 3 clinical study evaluating Ameluz®-PDT for the treatment of superficial basal cell carcinoma
●Received FDA approval for a new formulation of Ameluz

 

Management Commentary

 

“With a strengthened commercial team and advancements in clinical trials intended to expand the Ameluz label, Biofrontera made considerable progress during the third quarter, in line with our full-year expectations. Our commercial organization has succeeded in the onboarding of significant, large new customers and increased the use of PDT as we enter the fourth quarter, historically our seasonally strongest,” said Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera.

 

“In the first nine months of 2023 we increased the number of BF-RhodoLED® lamps in physician offices by 101, up sharply from 55 in the preceding quarter, enabling increased adoption of Ameluz-PDT. We are proud of the resulting third quarter financial performance as product revenues more than doubled compared with the prior year,” added Fred Leffler, Chief Financial Officer of Biofrontera Inc.

 

  

 

 

Third Quarter Financial Results

 

Total revenues for the third quarter of 2023 were $8.9 million, an increase of $4.6 million, or 106%, compared with $4.3 million for the third quarter of 2022. This growth reflects higher sales of Ameluz due to increased adoption by dermatologists and the buy-in impact due to a price increase.

 

Total operating expenses were $13.5 million for the third quarter of 2023 compared with $8.0 million for the third quarter of 2022. Cost of revenues was $4.6 million for the third quarter of 2023 compared with $2.2 million for the prior-year quarter, driven by higher Ameluz product revenue. Selling, general and administrative expenses were $8.7 million for the third quarter of 2023 compared with $7.9 million for the third quarter of 2022, with the increase primarily driven by higher personnel costs due to higher sales and medical headcount.

 

The net loss for the third quarter of 2023 was $6.3 million, or $(4.64) per share, compared with a net loss of $2.6 million, or $(2.26) per share, for the prior-year quarter, with all per-share figures on a split-adjusted basis.

 

Adjusted EBITDA for the third quarter of 2023 was negative $3.9 million compared with negative $5.0 million for the third quarter of 2022, reflecting higher revenues partially offset by increased SG&A costs. Adjusted EBITDA, a non-GAAP financial measure, is defined as net income or loss excluding interest income and expense, income taxes, depreciation and amortization, and certain other non-recurring or non-cash items.

 

Nine Month Financial Results

 

Total revenues were $23.5 million for the first nine months of 2023 compared with $18.5 million for the first nine months of 2022. The increase was driven by higher adoption of Ameluz by dermatologists and a higher average Ameluz selling price.

 

Total operating expenses were $42.3 million for the first nine months of 2023 compared with $31.5 million for the first nine months of 2022. Cost of revenues increased from the prior year to $12.1 million for the first nine months of 2023. Selling, general and administrative expenses for the first nine months of 2023 were $30.1 million compared with $25.7 million for the first nine months of 2022, an increase of 17.2% compared with the prior year, primarily driven by personnel-related expenses, sales-related travel, medical education expenses and higher legal expenses.

 

The net loss for the first nine months of 2023 was $23.7 million, or $(17.57) per share, compared with net income of $2.1 million, or $2.19 per diluted share, for the first nine months of 2022.

 

Adjusted EBITDA was negative $15.8 million for the first nine months of 2023 compared with negative $14.1 million for the first nine months of 2022.

 

  

 

 

The below table presents a reconciliation from net income (loss) to Adjusted EBITDA for the three and nine months ended September 30, 2023 and 2022:

 

  

Three months ended

September 30,

  

Nine months ended

September 30,

 
   2023   2022   2023   2022 
Net income (loss)  $(6,342)  $(2,566)  $(23,657)  $2,145 
Interest expense, net   142    89    256    160 
Income tax expense   1    1    20    31 
Depreciation and amortization   251    130    769    394 
EBITDA   (5,948)   (2,346)   (22,612)   2,730 
Change in fair value of contingent consideration   200    (2,200)   100    (4,100)
Change in fair value of warrant liabilities   (598)   (3,814)   (2,001)   (17,896)
Warrant inducement expense   -    2,629    -    2,629 
Change in fair value of investment, related party   2,212    -    6,635    - 
Legal settlement expenses   -    -    1,225    - 
Stock compensation expense   207    401    817    1,469 
Expensed issuance costs   -    320    -    1,045 
Adjusted EBITDA  $(3,927)  $(5,010)  $(15,836)  $(14,123)
Adjusted EBITDA margin   -44.1%   -115.9%   -67.5%   -76.2%

  

  

 

 

As of September 30, 2023, Biofrontera had cash and cash equivalents of $3.4 million compared with $17.2 million as of December 31, 2022. In addition, the Company had a $3.3 million investment in shares of Biofrontera AG as of September 30, 2023.

 

Financial Expectations

 

Biofrontera Inc. affirms expectations for full-year 2023 growth in revenue to be at least 25% compared with 2022, and expects to be cash flow positive within approximately one and a half years. Subsequent to the close of the quarter, on November 2nd the company closed on a $4.5 million registered direct offering priced at-the-market.

 

Conference Call and Webcast

 

Biofrontera Inc. will hold a conference call on Friday, November 10, 2023 at 10:00 a.m. Eastern time to discuss these results and answer questions.

 

Date:Friday, November 10, 2023
Time:10:00 a.m. Eastern time
 Conference Call:877-877-1275 (U.S. toll-free)
  412-858-5202 (international)
 Webcast:Live and 90-day replay webcast are available here and at investors.biofrontera-us.com.

 

About Biofrontera Inc.

 

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatologic conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.

 

Forward-Looking Statements

 

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of any extraordinary external events; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s expectations; the Company’s ability to comply with public company requirements; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

 

Contact:

 

LHA Investor Relations

Tirth T. Patel

212-201-6614

tpatel@lhai.com

 

(Tables follow)

 

  

 

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value and share amounts)

 

  

September 30,

2023

  

December 31,

2022

 
   (Unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $3,422   $17,208 
Investment, related party   3,341    10,548 
Accounts receivable, net   3,793    3,748 
Other receivables, related party   2,713    3,658 
Inventories, net   16,068    7,168 
Prepaid expenses and other current assets   274    810 
           
Total current assets   29,611    43,140 
           
Other receivables long term, related party   -    2,813 
Property and equipment, net   154    204 
Operating lease right-of-use assets   1,129    1,375 
Intangible asset, net   2,718    3,032 
Other assets   492    320 
           
Total assets  $34,104   $50,884 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable   1,634    1,278 
Accounts payable, related parties   6,988    1,312 
           
Acquisition contract liabilities, net   7,211    6,942 
Operating lease liabilities   555    498 
Accrued expenses and other current liabilities   11,039    10,864 
Line of credit   1,697    - 
           
Total current liabilities   29,124    20,894 
           
Long-term liabilities:          
Acquisition contract liabilities, net   2,500    2,400 
Warrant liabilities   842    2,843 
Operating lease liabilities, non-current   562    848 
Other liabilities   38    21 
           
Total liabilities   33,066    27,006 
           
Commitments and contingencies (Note 18)          
           
Stockholders’ equity:          
Preferred Stock, $0.001 par value, 20,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2023 and December 31, 2022   -    - 
Common Stock, $0.001 par value, 15,000,000 shares authorized; 1,367,628 and 1,334,950 shares issued and outstanding as of September 30, 2023 and December 31, 2022   1    1 
Additional paid-in capital   104,213    103,396 
Accumulated deficit   (103,176)   (79,519)
           
Total stockholders’ equity   1,038    23,878 
           
Total liabilities and stockholders’ equity  $34,104   $50,884 

 

  

 

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts and number of shares)

(Unaudited)

 

   Three months ended September 30,   Nine months ended September 30, 
   2023   2022   2023   2022 
                 
Product revenues, net  $8,879   $4,290   $23,423   $18,467 
Revenues, related party   17    32    52    63 
                     
Total revenues, net   8,896    4,322    23,475    18,530 
                     
Operating expenses                    
Cost of revenues, related party   4,495    2,127    11,814    9,504 
Cost of revenues, other   95    98    262    425 
Selling, general and administrative   8,619    7,765    29,874    25,050 
Selling, general and administrative, related party   74    171    193    612 
Research and development   33    -    44    - 
Change in fair value of contingent consideration   200    (2,200)   100    (4,100)
                     
Total operating expenses   13,516    7,961    42,287    31,491 
                     
Loss from operations   (4,620)   (3,639)   (18,812)   (12,961)
                     
Other income (expense)                    
Change in fair value of warrant liabilities   598    3,814    2,001    17,896 
Warrant inducement expense   -    (2,629)   -    (2,629)
Realized/Unrealized losses in investment, related party   (2,212)   -    (6,635)   - 
Interest expense, net   (142)   (89)   (256)   (160)
Other income, net   35    (22)   65    30 
                     
Total other income (expense)   (1,721)   1,074    (4,825)   15,137 
                     
Income (loss) before income taxes   (6,341)   (2,565)   (23,637)   2,176 
Income tax expense   1    1    20    31 
                     
Net income (loss)  $(6,342)  $(2,566)  $(23,657)  $2,145 
                     
Income (loss) per common share:                    
Basic  $(4.64)  $(2.26)  $(17.57)  $2.19 
Diluted  $(4.64)  $(2.26)  $(17.57)  $2.19 
                     
Weighted-average common shares outstanding:                    
Basic   1,366,842    1,136,291    1,346,264    978,018 
Diluted   1,366,842    1,136,291    1,346,264    980,251 

 

# # #

 

  

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 bfri-20231109.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 bfri-20231109_def.xml XBRL DEFINITION FILE EX-101.LAB 6 bfri-20231109_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common stock, par value $0.001 per share Preferred Stock Purchase Rights Warrants to purchase common stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 bfri-20231109_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 09, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2023
Entity File Number 001-40943
Entity Registrant Name Biofrontera Inc.
Entity Central Index Key 0001858685
Entity Tax Identification Number 47-3765675
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 120 Presidential Way
Entity Address, Address Line Two Suite 330
Entity Address, City or Town Woburn
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01801
City Area Code (781)
Local Phone Number 245-1325
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common stock, par value $0.001 per share  
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol BFRI
Security Exchange Name NASDAQ
Preferred Stock Purchase Rights  
Title of 12(b) Security Preferred Stock Purchase Rights
Security Exchange Name NASDAQ
Warrants to purchase common stock  
Title of 12(b) Security Warrants to purchase common stock
Trading Symbol BFRIW
Security Exchange Name NASDAQ
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001858685 2023-11-09 2023-11-09 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2023-11-09 2023-11-09 0001858685 BFRI:PreferredStockPurchaseRightsMember 2023-11-09 2023-11-09 0001858685 BFRI:WarrantsToPurchaseCommonStockMember 2023-11-09 2023-11-09 iso4217:USD shares iso4217:USD shares false 0001858685 8-K 2023-11-09 Biofrontera Inc. DE 001-40943 47-3765675 120 Presidential Way Suite 330 Woburn MA 01801 (781) 245-1325 false false false false Common stock, par value $0.001 per share BFRI NASDAQ Preferred Stock Purchase Rights NASDAQ Warrants to purchase common stock BFRIW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " 1H1 !X;"]W M;W)K8F]O:RYX;6Q02P$"% ,4 " #EB6E7)!Z;HJT #X 0 &@ M @ %Z$@ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " #EB6E799!YDAD! #/ P $P @ %?$P 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" "I% ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 4 24 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biofrontera.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bfri-20231109.xsd bfri-20231109_def.xml bfri-20231109_lab.xml bfri-20231109_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "BFRI", "nsuri": "http://biofrontera.com/20231109", "dts": { "schema": { "local": [ "bfri-20231109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "bfri-20231109_def.xml" ] }, "labelLink": { "local": [ "bfri-20231109_lab.xml" ] }, "presentationLink": { "local": [ "bfri-20231109_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 3, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 4, "entityCount": 1, "segmentCount": 3, "elementCount": 66, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://biofrontera.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://biofrontera.com/role/Cover" ], "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "BFRI_CommonStockParValue0.001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://biofrontera.com/20231109", "localname": "CommonStockParValue0.001PerShareMember", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.001 per share" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "BFRI_PreferredStockPurchaseRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://biofrontera.com/20231109", "localname": "PreferredStockPurchaseRightsMember", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Purchase Rights" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "BFRI_WarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://biofrontera.com/20231109", "localname": "WarrantsToPurchaseCommonStockMember", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase common stock" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://biofrontera.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-23-040113-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-040113-xbrl.zip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end